Ionis Pharmaceuticals IONS Intangible Purchases
Intangible Purchases at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's intangible purchases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's intangible purchases?
- Ionis Pharmaceuticals (IONS) reported intangible purchases of $1.49M in Q1 2026.
- How has Ionis Pharmaceuticals's intangible purchases changed year-over-year?
- Ionis Pharmaceuticals's intangible purchases increased by 128.3% year-over-year, from $651K to $1.49M.
- What is the long-term trend for Ionis Pharmaceuticals's intangible purchases?
- Over 3 years (2021 to 2025), Ionis Pharmaceuticals's intangible purchases has grown at a -1.7% compound annual growth rate (CAGR), from $5.95M to $5.64M.
- What does intangible purchases mean?
- Cash spent on acquiring non-physical assets like patents or software.
- How do you interpret intangible purchases?
- Increases suggest aggressive investment in R&D, technology, or strategic intellectual property acquisitions.
- How does intangible purchases compare across companies?
- Particularly high for pharmaceutical and technology companies investing in R&D pipelines.